Yeong Ok Baik
Overview
Explore the profile of Yeong Ok Baik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
73
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lovell J, Miura K, Baik Y, Lee C, Choi Y, Her H, et al.
J Med Virol
. 2024 Sep;
96(9):e29927.
PMID: 39318203
EuCorVac-19 (ECV-19) is a recombinant receptor binding domain (RBD) COVID-19 vaccine that displays the RBD (derived from the SARS-CoV-2 Wuhan strain) on immunogenic liposomes. This study compares the safety and...
2.
Song K, Chapagain R, Tamrakar D, Shrestha R, Kanodia P, Chaudhary S, et al.
Lancet Glob Health
. 2024 Apr;
12(5):e826-e837.
PMID: 38614631
Background: In October, 2017, WHO launched a strategy to eliminate cholera by 2030. A primary challenge in meeting this goal is the limited global supply capacity of oral cholera vaccine...
3.
Shah S, Nandy R, Sethi S, Chavan B, Pathak S, Dutta S, et al.
Lancet Reg Health Southeast Asia
. 2023 Dec;
19:100256.
PMID: 38076719
Background: Considering the cholera menace in India and to seek licensure of the oral cholera vaccine (OCV), Euvichol-Plus, we conducted a clinical trial to compare the immunogenicity and safety of...
4.
Lovell J, Miura K, Baik Y, Lee C, Lee J, Park Y, et al.
Int J Infect Dis
. 2023 Nov;
138:73-80.
PMID: 37944586
Objective: EuCorVac-19 (ECV-19), an adjuvanted liposome-displayed receptor binding domain (RBD) COVID-19 vaccine, previously reported interim Phase 2 trial results showing induction of neutralizing antibodies 3 weeks after prime-boost immunization. The...
5.
Baik Y, Lee Y, Lee C, Kyung Kim S, Park J, Sun M, et al.
Vaccine
. 2023 Feb;
41(10):1753-1759.
PMID: 36774331
The typhoid conjugate vaccine (TCV) ensures a long-lasting protective immune response, requires fewer doses and is fit for children under 2 years of age. From Phase I study, EuTCV displayed...
6.
Lovell J, Baik Y, Keun Choi S, Lee C, Lee J, Miura K, et al.
BMC Med
. 2022 Nov;
20(1):462.
PMID: 36447243
Background: Numerous vaccine strategies are being advanced to control SARS-CoV-2, the cause of the COVID-19 pandemic. EuCorVac-19 (ECV19) is a recombinant protein nanoparticle vaccine that displays the SARS-CoV-2 receptor-binding domain...
7.
Keun Choi S, Baik Y, Kim C, Kyung Kim S, Oh I, Yoon H, et al.
Vaccine
. 2021 Apr;
39(19):2620-2627.
PMID: 33849723
An injectable typhoid conjugate vaccine (TCV) provides longer-lasting protection, requires fewer doses, and is suitable for children aged >2 years. In addition, TCV is preferred at most ages owing to...
8.
Whang Y, Kyung Kim S, Yoon H, Keun Choi S, Baik Y, Lee C, et al.
PLoS One
. 2020 Dec;
15(12):e0243909.
PMID: 33301525
Glycoconjugate vaccines are vaccines in which a bacterial polysaccharide antigen is conjugated to a carrier protein to enhance immunogenicity by promoting T cell-dependent immune response. However, the free (unreacted) polysaccharides...
9.
Burton R, Kim H, Lee S, Kim H, Seok J, Ku K, et al.
Vaccine
. 2020 Nov;
38(51):8145-8153.
PMID: 33162203
Pneumococcal conjugate vaccines (PCVs) have been effective in reducing the disease burden caused by Streptococcus pneumoniae. The first licensed PCV (PCV7) was composed of capsular polysaccharides from seven serotypes. This...
10.
Lee C, Chun H, Park M, Kim R, Whang Y, Keun Choi S, et al.
Front Bioeng Biotechnol
. 2020 Mar;
8:39.
PMID: 32117921
is the causative agent of many diseases, most notably pneumonia. Most of the currently used vaccines to protect against this pathogen employ pneumococcal capsular polysaccharides (CPSs) as antigens, but purifying...